Format

Send to

Choose Destination
See comment in PubMed Commons below
J Wound Care. 2002 Feb;11(2):70-4.

Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in four European countries.

Author information

1
Swedish Institute for Health Economics, Lund, Sweden. og@ihe.se

Abstract

OBJECTIVE:

This study aimed to estimate the cost-effectiveness of treating non-superficial diabetic foot ulcers with Promogran plus good wound care (GWC) compared with GWC alone in four European countries (France, Germany, Switzerland and UK).

METHODS:

An existing Markov-based health economic model of non-superficial diabetic foot ulcers was adapted to incorporate the relative efficacy of Promogran compared with GWC alone as demonstrated in a randomised controlled trial. Treatment with Promogran was modelled for a maximum of three months. Country-specific treatment costs were used to estimate the incremental cost per ulcer-free day gained over 12 months. Some parameter assumptions were changed to assess the sensitivity of the results.

RESULTS:

Within the first three months of treatment, 26% of ulcers in the Promogran cohort healed compared with 20.7% in the GWC cohort. Over the 12 months, the average number of months spent in the healed state was 3.41 (GWC) and 3.75 (Promogran). Promogran treatment was found to be cost-saving in all four countries, using year 2000 Euro values.

CONCLUSION:

Promogran with GWC may be cost-effective, perhaps even cost-saving, under a wide variety of assumptions for the treatment of neuropathic foot ulcers.

DECLARATION OF INTEREST:

This study was funded by Ethicon Gmbh (Johnson and Johnson), Germany.

PMID:
11901743
DOI:
10.12968/jowc.2002.11.2.26675
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center